Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03661879 · ClinicalTrials.gov registry record · Phase 1
Research Study of a New Medicine (NNC9204-1706) in People With Overweight or Obesity
A Phase 1 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT03661879 is a Phase 1 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 60 participants.
The verdict
NCT03661879, a Phase 1 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
The study is testing a new medicine for weight control in people with overweight or obesity. The aim of the study is to find out how safe the study medicine is and how it works in the body. Participants will either get NNC9204-1706 (the new study medicine) or placebo (a dummy medicine) - which treatment participants get is decided by chance. NNC9204-1706 is a new medicine which cannot be prescribed by doctors. Participants will get an injection under the skin of participants' stomach each morning for 10 weeks. A medical tool called NovoPen®4 will be used for the injection. Participants must change the part of the pen including the medicine (the cartridge) each day. The study will last for about 16 weeks. Participants will have at least 17 clinic visits and 10 phone calls with the study doctor. At certain times during the study, participants will have blood drawn and 3 different kinds of heart tests (electrocardiograms). Study doctor will ask participants to answer mental health surveys.
Interventions
- DRUG NNC9204-1706
- DRUG Placebo (NNC9204-1706)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2018-09-12 |
| Est. Completion | 2019-10-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03661879
The ClinicalTrials.gov registry entry for NCT03661879 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which NNC9204-1706 is the first listed.
NCT03661879 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03661879 about?
NCT03661879 is a clinical study titled "Research Study of a New Medicine (NNC9204-1706) in People With Overweight or Obesity". The study is testing a new medicine for weight control in people with overweight or obesity. The aim of the study is to find out how safe the study medicine is and how it works in the body. Participants will either get NNC9204-1706 (the new study medicine) or placebo (a dummy medicine) - which treat...
What is the current status of trial NCT03661879?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2018-09-12. Estimated completion is 2019-10-09.
What interventions are being tested in trial NCT03661879?
The interventions under investigation include: NNC9204-1706 (DRUG), Placebo (NNC9204-1706) (DRUG).
Who is sponsoring clinical trial NCT03661879?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.